Nutriband Inc.

NASDAQ:NTRB

Biotechnology

Healthcare
$5.59 +22.32%

+$0.85 today

Market cap
$67.95M
Beta
1.97
P/E (TTM)
-1.8
EPS (TTM)
-$0.66
52W Low $2.80High $8.63

Volume 0.02M

Average 0.01M

NTRB EBITDA Margin

EBITDA as a percentage of revenue.

Nutriband Inc.NASDAQ: NTRB

EBITDA Margin · Q1 FY2026 · quarter ended Apr 2026

EBITDA Margin narrows to -277.5%

EBITDA Margin was -277.5% in Q1 FY2026, down 78.9 pp from a year earlier. On a trailing-twelve-month basis it was -437.7%, down 34.1 pp year over year. Over 3 fiscal years it narrowed by 196.0 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 1 analysts of 25.1% for the fiscal year ending Jan 2027, up from -393.5% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterApr 2026
-277.5%-46.2 pp QoQ
Last fiscal yearJan 2026
-393.5%+82.1 pp YoY
LTMApr 2026
-437.7%-34.1 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-78.9 pp——
1 year+82.1 pp+418.6 pp+336.5 pp
3 years-196.0 pp——
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-393.5%
Year-over-year change
+82.1pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How NTRB compares with its peers on the latest reported figures

  • NTRB's LTM Apr 2026 EBITDA Margin of -437.7% is the 2nd highest of the 4 companies compared; the peer median is -1298.7%.
  • Its year-over-year change of -34.1 pp is the lowest of 3, against a peer median of +949.3 pp.
  • Over three fiscal years its change of -196.0 pp compares with a peer median of +223.8 pp.
NTRB Competitors Peer median
EBITDA Margin for NTRB and competitors
Company Period LTM level YoY 3-year change
FBIOFortress Biotech, Inc.LTM Mar 2026223.7% +379.4 pp+223.8 pp
NTRBNutriband Inc.LTM Apr 2026-437.7% -34.1 pp-196.0 pp
TCRXTScan Therapeutics, Inc.LTM Mar 2026-1298.7% +1519.2 pp-759.6 pp
ADAGAdagene Inc.LTM Jun 2024-4420.7% —+613.1 pp
RLMDRelmada Therapeutics, Inc.FY2025— ——
ACRVAcrivon Therapeutics, Inc. Common StockFY2025— ——
XBITXBiotech Inc.FY2025— ——
GANXGain Therapeutics, Inc.FY2025— ——
ACETAdicet Bio, Inc.FY2025— ——
Peer median (excluding NTRB) -1298.7%+949.3 pp+223.8 pp

Competitors are the stored peer set for NTRB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Jan 2022
FY2022
Jan 2023
FY2023
Jan 2024
FY2024
Jan 2025
FY2025
Jan 2026
Revenue1.42M2.08M2.09M2.14M2.04M
Cost of Revenue917.84K1.33M1.22M1.44M1.47M
Gross Profit504.31K750.41K862.11K699.3K566.31K
Gross Margin35.5%36.1%41.3%32.7%27.8%
Research & Development411.38K982.23K1.96M3.12M1.89M
Selling, General & Admin4.02M3.92M3.77M4.27M6.99M
Operating Expenses4.43M4.9M5.73M7.39M8.88M
Depreciation & Amortization318.26K368.96K287.72K285.05K193.8K
EBITDA(5.74M)(4.11M)(5.12M)(10.18M)(8.01M)
EBITDA Margin-403.6%-197.5%-245.6%-475.5%-393.5%
Operating Income(3.93M)(4.15M)(4.87M)(6.69M)(8.32M)
Operating Margin-276.3%-199.5%-233.6%-312.6%-408.4%
Interest Income0016.85K191.67K0
Interest Expense118.42K8.29K75.82K21.41K22.54K
Other Income / Expenses(2.25M)(335.62K)(613.39K)(3.79M)88.33K
Income Before Tax(6.18M)(4.48M)(5.49M)(10.48M)(8.23M)
Pre-Tax Margin-434.3%-215.6%-263.0%-489.9%-404.1%
Income Tax Expense00000
Net Income(8.42M)(4.81M)(5.49M)(10.48M)(8.23M)
Net Margin-592.2%-231.3%-263.0%-489.9%-404.1%
EPS (Basic)(1.06)(0.57)(0.69)(0.99)(2.58)
EPS (Diluted)(1.06)(0.57)(0.69)(0.99)(2.58)
Weighted Avg Shares7.93M8.46M7.95M10.61M11.64M
Weighted Avg Shares (Diluted)7.93M8.46M7.95M10.61M11.64M

Nutriband Inc.

NASDAQ:NTRB

Intrinsic Alpha fair value

Locked

Current Price

$5.59

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.